RT Journal Article SR Electronic T1 HIF2α Antagonism Has Antitumor Activity in Advanced ccRCC JF Cancer Discovery JO Cancer Discov FD American Association for Cancer Research DO 10.1158/2159-8290.CD-RW2018-007 YR 2018 UL http://cancerdiscovery.aacrjournals.org/content/early/2018/01/11/2159-8290.CD-RW2018-007.abstract AB The HIF2α antagonist PT2385 achieved responses in 14% of patients with heavily pretreated ccRCC.